TG Therapeutics Gets CHMP Backing for Briumvi in Relapsing Multiple Sclerosis
March 31 2023 - 08:14AM
Dow Jones News
By Colin Kellaher
TG Therapeutics Inc. on Friday said the European Medicines
Agency's Committee for Medicinal Products for Human Use has
recommended approval of Briumvi for the treatment of relapsing
forms of multiple sclerosis in adults.
The New York biopharmaceutical company said it expects a
decision by the European Commission, which generally follows the
CHMP's advice, in about two months.
The U.S. Food and Drug Administration in late December approved
Briumvi for adults with relapsing forms of multiple sclerosis, a
neurological disease that affects more than 2 million people around
the world.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 31, 2023 07:59 ET (11:59 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.